Sign In
Buy NMRA
$1.74
-0.0100 (-0.571%)
At Close: Jun 03, 2026
Neumora Therapeutics touts Phase 1B NMRA-511 gains in Alzheimer’s agitation, eyes higher doses
04:32am, Tuesday, 06'th Jan 2026
Neumora Therapeutics (NASDAQ: NMRA) reported top-line results from a Phase IB signal-seeking study of NMRA-511 in agitation associated with dementia due to Alzheimer's disease, with management highlig
Neumora Therapeutics, Inc. (NMRA) Discusses Positive Phase 1b Results for NMRA-511 in Alzheimer's Disease Agitation Transcript
01:28pm, Monday, 05'th Jan 2026
Neumora Therapeutics, Inc. (NMRA) Discusses Positive Phase 1b Results for NMRA-511 in Alzheimer's Disease Agitation Transcript
Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones
06:35am, Monday, 05'th Jan 2026
Multiple clinical data readouts expected in 2026 present opportunity for substantial value creation KOASTAL-2 and -3 on track for consolidated topline readout in the second quarter of 2026 Plans to co
Neumora Therapeutics Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimer's Disease Agitation
06:30am, Monday, 05'th Jan 2026
NMRA-511 demonstrated a 15.7 reduction on mean CMAI total score, representing a clinically meaningful effect NMRA-511 demonstrated unsurpassed clinical effect size on CMAI total score in a pre-speci
Critical Contrast: Aptevo Therapeutics (NASDAQ:APVO) vs. Neumora Therapeutics (NASDAQ:NMRA)
03:30am, Saturday, 20'th Dec 2025
Neumora Therapeutics (NASDAQ: NMRA - Get Free Report) and Aptevo Therapeutics (NASDAQ: APVO - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast t
Analyst Sees Value In Neumora's Expanding Obesity And Metabolic Pipeline
01:45pm, Monday, 01'st Dec 2025
RBC Capital Markets upgraded Neumora Therapeutics, Inc. (NASDAQ: NMRA) from Sector Perform to Outperform, with an increased price forecast from $4 to $7.
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives $7.57 Consensus Target Price from Analysts
02:46am, Wednesday, 26'th Nov 2025
Shares of Neumora Therapeutics, Inc. (NASDAQ: NMRA - Get Free Report) have been assigned a consensus recommendation of "Hold" from the ten ratings firms that are covering the stock, Marketbeat Ratings
Neumora Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
07:00am, Thursday, 06'th Nov 2025
Announced class-leading data from diet-induced obesity (DIO) mouse model with NMRA-215, a potentially best-in-class, highly brain-penetrant, oral NLRP3 inhibitor, and expect to initiate Phase 1 study
Neumora Therapeutics to Participate in Upcoming Conferences in November
07:00am, Monday, 03'rd Nov 2025
WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven programs that
Neumora Therapeutics, Inc. (NASDAQ:NMRA ) Discusses NMRA-215 Preclinical Results and Portfolio Updates, Including Obesity and Alzheimer's Disease Programs October 27, 2025 8:00 AM EDT Company Particip
Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-898
07:00am, Monday, 27'th Oct 2025
NMRA-898 is structurally distinct from NMRA-861 and is the second M4 PAM in Neumora's M4 franchise; both programs have potential best-in-class pharmacology
Neumora Therapeutics Announces Class-Leading Weight Loss Demonstrated with NMRA-215 in Preclinical Diet-Induced Obesity Model
06:30am, Monday, 27'th Oct 2025
NMRA-215 demonstrated class-leading weight loss of up to 19% as a monotherapy with semaglutide-like induction NMRA-215 demonstrated best-in-class weight loss of up to 26% in combination with semaglu
Neumora Therapeutics to Host Virtual R&D Day on October 27
07:00am, Wednesday, 01'st Oct 2025
WATERTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven programs that
Neumora Therapeutics to Participate in Upcoming Conferences in September
07:00am, Tuesday, 02'nd Sep 2025
WATERTOWN, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven programs tha
Neumora Therapeutics, Inc. (NMRA) Q2 2025 Earnings Call Transcript
02:41am, Thursday, 07'th Aug 2025
Neumora Therapeutics, Inc. (NASDAQ:NMRA ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Daljit Singh Aurora - Corporate Participant Chief Operationg & Development off
